Corrigendum to “Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis” [Eur J Cancer 47 (12) (2011) 1826–1836]

摘要: Stephen J. Clarke *, Sonia Yip , Chris Brown Guy A. van Hazel David T. Ransom Goldstein G. Mark Jeffrey Niall C. Tebbutt Martin Buck Raymond M. Lowenthal Amy Boland Val Gebski John Zalcberg R. Simes on behalf of the Australasian Gastro-Intestinal Trials Group a Department Medicine, Concord Hospital, Concord, Sydney, Australia b National Health and Medical Research Council (NHMRC) Clinical Centre, University c School Medicine Pharmacology, Western Australia, Perth, d St. God e Oncology, Prince Wales f Oncology Service, Christchurch Christchurch, New Zealand g Austin Health, Melbourne, h Sir Charles Gairdner i Royal Hobart Hospital Tasmania, Hobart, j Peter MacCallum Cancer Centre